Anti-fibrinolytic agents in post partum haemorrhage: a systematic review. by Ferrer, Pili et al.
Ferrer, P; Roberts, I; Sydenham, E; Blackhall, K; Shakur, H (2009)
Anti-fibrinolytic agents in post partum haemorrhage: a systematic





Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
BioMed Central
Page 1 of 6
(page number not for citation purposes)
BMC Pregnancy and Childbirth
Open AccessResearch article
Anti-fibrinolytic agents in post partum haemorrhage: a systematic 
review
Pili Ferrer, Ian Roberts*, Emma Sydenham, Karen Blackhall and 
Haleema Shakur
Address: London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK
Email: Pili Ferrer - piliferrer@eresmas.com; Ian Roberts* - ian.roberts@lshtm.ac.uk; Emma Sydenham - emma.sydenham@lshtm.ac.uk; 
Karen Blackhall - karen.blackhall@lshtm.ac.uk; Haleema Shakur - haleema.shakur@lshtm.ac.uk
* Corresponding author    
Abstract
Background: Post partum haemorrhage is a leading cause of maternal death worldwide. It also
contributes to maternal morbidity as women may require a hysterectomy to control bleeding, or
may require a blood transfusion, which can transmit viral infections. Anti-fibrinolytic agents have
been proposed as a treatment for post partum haemorrhage. We conducted a systematic review
to assess the effectiveness and safety of anti-fibrinolytic agents in post partum bleeding.
Methods: All randomised controlled trials of anti-fibrinolytic agents given for bleeding during the
postpartum period were included in this review. We searched Medline, PubMed, EMBASE,
Cochrane Central Register of Controlled trials, Web of Science, metaRegister of controlled trials,
LILACS, Reproductive Health Library, African healthline, POPLINE, MedCarib, CINAHL,
Clinicaltrials.gov and the reference lists of eligible trials. Two authors extracted data.
Methodological quality was assessed by evaluating allocation concealment. The primary outcome
was maternal mortality. Secondary outcomes were blood loss, blood transfusion, hysterectomy,
mean haemoglobin concentration, thrombo-embolic events and other adverse effects.
Results: We identified three randomised controlled trials involving 461 participants. The trials
compared tranexamic acid with no treatment and reported blood loss after delivery. In all three
trials, allocation concealment was either inadequate or unclear. The administration of tranexamic
acid was associated with a reduction in blood loss of 92 millilitres (95%CI 76 to 109). The most
frequently reported adverse effect of tranexamic acid was nausea, although the increase was easily
compatible with the play of chance (RR 4.63, 95%CI 0.23 to 95.14).
Conclusion: Tranexamic acid may reduce blood loss in post partum haemorrhage. However, the
quality of the currently available evidence is poor. Adequately powered, high quality randomised
controlled trials are needed.
Background
Each year, worldwide, about 536,000 women die from
causes related to pregnancy and childbirth. Almost all
(99%) of the deaths are in low and middle income coun-
tries.[1] Postpartum haemorrhage is the most common
cause of maternal death.[2] Of the 14 million women
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who have postpartum haemorrhage each year, 1–2% die,
with an average interval from onset of bleeding to death
of 2 to 4 hours.[2] Haemorrhage is also an important
cause of maternal mortality in high income countries,
accounting for about 13% of maternal deaths.[3]
Postpartum haemorrhage also contributes to hospital
morbidity because patients may require a blood transfu-
sion, which can transmit blood borne viral infections.
Approximately 1% of women with spontaneous vaginal
deliveries receive a blood transfusion, but the rate
increases to about 5% for women with instrumental deliv-
eries or caesarean sections.[4] The risk of infection from
transfused blood is higher in countries unable to thor-
oughly screen the blood used for transfusion.[5] In high
income countries, the risk of transfusion transmitted
infections is lower, but adverse reactions related to blood
transfusion are a common adverse event.[6]
The World Health Organization (WHO) defines postpar-
tum haemorrhage as blood loss of 500 ml or more.[7] The
diagnosis is based on a clinical estimate of blood loss. The
WHO states that the loss of 500 ml of blood should be
considered an alert, after which the health of the woman
may be endangered.[7] In many parts of the world, the
loss of 500 ml of blood can be a serious threat to health
due to the high prevalence of severe anaemia. Severe anae-
mia is a common consequence of postpartum bleeding
and affects about 11% of the 14 million women with
postpartum haemorrhage each year.[8]
The main causes of postpartum haemorrhage are uterine
atony, trauma to the genital tract during delivery and
retained placenta.[9] Risk factors for postpartum haemor-
rhage include primiparity, prolonged or augmented
labour, multiple births, polyhydramnios, anaesthesia,
macrosomia, obesity, and placental abruption. Neverthe-
less, the majority of women with postpartum haemor-
rhage have low-risk pregnancies.[2] There is evidence
from randomised controlled trials that prophylactic oxy-
tocin can reduce the incidence of post partum bleeding
(relative risk [RR] for blood loss greater than 500 ml =
0.50, 95% Confidence Interval [CI] 0.43 to 0.59).[10]
The treatment of postpartum haemorrhage may include
drugs to increase uterine contractility, volume replace-
ment for blood loss, and various surgical procedures
including uterine compression sutures, arterial ligation,
selective artery embolisation, intrauterine tamponade and
hysterectomy.[11-13] The cumulative incidence of emer-
gency hysterectomy varies between regions but is esti-
mated at between 0.04 and 1.25% for all deliveries.[14]
Systemic anti-fibrinolytic agents are widely used in sur-
gery to prevent clot breakdown (fibrinolysis) to reduce
blood loss. A systematic review[15] of randomised con-
trolled trials of anti-fibrinolytic agents in elective surgical
patients identified 211 randomised controlled trials
including 20,781 randomised participants. The results
showed that aprotinin reduced the risk of blood transfu-
sion by a relative 34% (RR 0.66, 95%CI 0.61 to 0.71) and
tranexamic acid by a relative 39% (RR 0.61, 95%CI 0.54
to 0.69). In those requiring transfusion, aprotinin reduced
the transfused blood volume by 1.1 units (95%CI 0.83 to
1.31) and tranexamic acid by 1.1 units (95%CI 0.64 to
1.59). A pooled analysis showed that anti-fibrinolytic
agents reduce the need for re-operation due to bleeding
(RR 0.52, 95%CI 0.40 to 0.69) and there was a non-signif-
icant reduction in the risk of death (RR 0.90, 95%CI 0.67
to 1.20) in the anti-fibrinolytic treated group. There was
no evidence of increased risk of developing thrombotic
events.
The 5th Millennium Development Goal is to reduce mater-
nal deaths by 75% by the year 2015.[16] To achieve this
goal, a reduction in maternal mortality of at least 5.5%
each year is necessary. As haemorrhage accounts for
around 25% of maternal deaths, an effective treatment for
the management of postpartum haemorrhage could con-
tribute significantly to the goal of reducing maternal mor-
tality. Anti-fibrinolytic agents might reduce the need for
hysterectomy, reduce the risk of severe anaemia and avoid
the need for blood transfusion.
This systematic review aimed to quantify the effectiveness
and safety of anti-fibrinolytic agents in the prevention or
treatment of postpartum bleeding.
Methods
We sought to identify all randomised controlled trials of
an anti-fibrinolytic agent (aprotinin, tranexamic acid and
epsilon-aminocaproic acid) with placebo or no treatment.
A randomised controlled trial was defined as a trial in
which the participants were assigned to one of two (or
more) interventions using random allocation, or some
quasi-random method of allocation. Participants were
women with any type of bleeding from the genital tract
during the postpartum period. The following electronic
databases were searched up to November 2008:
MEDLINE, PubMed, EMBASE, Cochrane Central Register
of Controlled Trials, Web of Science SCI/ISI, metaRegister
of Controlled Trials, Reproductive Health Library,
LILACS, African healthline, CINAHL, POPLINE, Med-
Carib and Clinicaltrials.gov. Our search strategy did not
include terms to identify participants (such as pregnancy
or postpartum) as we wanted to find all randomised con-
trolled trials of the use of antifibrinolytic agents, and clas-
sify them by the type of participant, thus ensuring
maximum sensitivity. No language restriction was
applied. Reference lists from relevant trials were also
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scanned. The list of medical subheadings (MeSH) and tex-
twords used in the search strategy can be found in [See
Additional file 1].
The primary outcome measure was mortality. Secondary
outcome measures were blood loss (mean and standard
deviation); amount of blood or blood components trans-
fused (both the proportion of participants receiving the
transfusion and number of units received); the occurrence
of postpartum haemorrhage; the need for conservative
surgical procedures (B-Lynch and other brace sutures,
artery ligation, selective embolisation of arteries, and
intrauterine tamponade independently of the technique
used); peripartum hysterectomy; mean postpartum hae-
moglobin concentration; thromboembolic events: deep
vein thrombosis, pulmonary thromboembolism, stroke,
myocardial infarct; and other adverse reactions.
Data were extracted on the following items: number of
randomised participants, types of participants and inter-
ventions, method of allocation concealment, loss to fol-
low-up (number and reasons), the use of blinding, and
whether an intention-to-treat analysis was carried out. In
the event of insufficient information in the published
report, the authors were contacted for clarification.
Data extraction was conducted by two review authors
using a standardised data extraction form. The authors
were not blind to authorship, journal of publication, or
results of the trials.
Allocation concealment was the main element used to
assess the methodological quality of included trials. Allo-
cation concealment was scored according to the scale used
by Schulz 1995.[17]
• A = trials that have taken measures that ensure allocation
concealment (central randomisation; serially numbered,
opaque, sealed envelopes; or other description with con-
vincing elements of concealment).
• B = trials in which allocation concealment is not
reported at all or the authors report an approach that does
not fall into one of the other categories.
• C = trials in which concealment is inadequate (such as
alternation or reference to case record numbers or dates of
birth).
For blood loss volume, the difference in means (expressed
in millilitres) was calculated with 95%CI. For other
adverse reactions the RR and 95%CI were calculated. The
between trial heterogeneity was assessed with the
I2statistic. Data were combined using a fixed-effects
model.
All analyses were performed with Review Manager© ver-
sion 5 and STATA© version 10.1 for Windows.[18,19]
Results
A total of 8,925 records were identified in the search. The
titles and abstracts were screened by two authors and the
full text of all potentially relevant trial reports were
retrieved and read in full. Three trials[20-22] were identi-
fied that met the inclusion criteria [see Additional file 2].
The three trials included a total of 461 participants of
whom 235 were randomised to receive tranexamic acid
and 226 were randomised to a control group.
Of the three included trials, two were of women who had
caesarean section delivery (Gai 2004; Gohel 2007) and
one was of women who had spontaneous vaginal delivery
(Yang 2001).
In Gai 2004 and Gohel 2007, one dose of 1 gram tran-
examic acid was administered intravenously 10 and 20
minutes, respectively, before incision. The trial by Yang
2001 compared four groups. One group (n = 94) received
a single dose of 1 gram tranexamic acid by intravenous
infusion (IV), another group (n = 92) received a single
dose of 0.5 gram tranexamic acid IV, the third group (n =
92) received a single dose of 0.5 gram aminomethylben-
zoic acid IV and the fourth group (n = 87) served as a con-
trol group. In this review, only a comparison of the group
that received 1 gram of tranexamic acid versus control was
included in the analysis.
The method used to generate the randomisation sequence
was specified in all three trials. In Yang 2001 the sequence
was generated by computer; in Gai 2004 a consecutive
numbered chart was used (no further explanation was
given); in Gohel 2007 'the rule of even and odds' was
used. The explanation given by the authors was that all
odd cases were taken up for tranexamic acid. Allocation
concealment was not described in Gai 2004 or Yang 2001.
Gohel 2007 reported allocation concealment was inade-
quate. According to the Shulz scale, Gai 2004 and Yang
2001 were scored B; Gohel 2007 was scored C.
Randomised participants were followed up for a period of
two hours after childbirth in all three trials. For further
information on characteristics of the included trials, [see
Additional file 3].
The primary outcome for this review was mortality. There
were no deaths in the Gohel 2007 trial and mortality was
not reported in the trials by Gai 2004 and Yang 2001.
Gohel 2007 reported a lower incidence of postpartum
haemorrhage (defined as ≥ 500 ml blood loss from pla-
cental delivery to two hours postpartum) in women
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receiving tranexamic acid (5/50) than in the control group
(14/50). Gai 2004 reported a lower incidence of postpar-
tum haemorrhage (defined as blood loss of ≥ 400 ml) in
the group receiving tranexamic acid (22/91) than the con-
trol group (36/89). Yang 2001 reported a lower incidence
of postpartum haemorrhage (defined as blood loss of ≥
400 ml in women receiving tranexamic acid (6/94) than
the control group (22/87). The pooled relative risk for
investigator defined (as above) postpartum haemorrhage
was RR = 0.44 (95%CI 0.31 to 0.64).
Gohel 2007 reported that no thrombotic events occurred,
and that no participants required blood transfusion. Gai
2004 and Yang 2001 did not report thrombotic events.
Combining the results of the three trials, the use of tran-
examic acid significantly reduced mean blood loss by 92
millilitres (95%CI 76 to 109) compared to no treatment.
There was no evidence of heterogeneity between trials (I2
= 0%, Chi2 = 1.44, degrees of freedom = 2, p = 0.49), [Fig-
ure 1].
Gohel 2007 reported no adverse reactions in any partici-
pant in the study. Gai 2004 reported transient mild
adverse reactions, but the number of participants affected
and the type of adverse reactions were not described.
Adverse reactions were reported in Yang 2001; two partic-
ipants in the intervention group developed nausea. Partic-
ipants in the intervention group had a higher risk of
nausea than participants in the control group (RR 4.63,
95% CI 0.23 to 95.1).
Discussion
This systematic review and meta-analysis of three ran-
domised controlled trials provides some evidence that a
single dose of 1 gram of tranexamic acid given intrave-
nously reduces mean blood loss within two hours of
delivery. However, the quality of the included trials was
poor and they provided no data on mortality, which was
the primary outcome measure of the review.
The duration of follow up was short and adverse events
may have occurred after the study period ended. Tran-
examic acid is not completely eliminated from the blood
until 9–18 hours after administration.[23] However,
because the half-life of tranexamic acid is two hours, levels
in the blood would be reduced after the study period.
Additional outcome data collected beyond two hours of
administration of tranexamic acid would have provided
further information on adverse events.
The three included trials were all of low methodological
quality. Selection, performance and detection bias may
have influenced the results of the included trials. We can-
not exclude performance and detection biases because
participants in the control group did not receive a pla-
cebo. The reports did not mention whether or not the
researchers were blind to allocation. As regards the meta-
analysis of the effect of tranexamic acid on blood loss, the
large standard deviations reported in the studies by Gai
and Yang suggests that the data may be skewed, in which
case our analysis of mean blood loss may be misleading.
Despite the importance of post partum haemorrhage as a
cause of maternal mortality, there is little information
from randomised controlled trials on the effects of antifi-
brinolytic agents as a treatment for this condition.
Although our results are consistent with the results of ran-
domised controlled trials of the use of tranexamic acid in
surgical bleeding, showing a reduction in mean blood
loss, the poor quality of the included trials warrants a cau-
tious interpretation.
All of the trials included in this systematic review consid-
ered the use of tranexamic acid in the prevention of post-
partum bleeding, and we found no trials of its use in the
treatment of postpartum haemorrhage. Nevertheless, the
recently updated postpartum haemorrhage treatment
guidelines prepared by the WHO state that tranexamic
acid may be used in the treatment of postpartum haemor-
rhage if other measures fail. However, the guidelines
point out that the quality of evidence on which this rec-
Meta-analysis comparing tranexamic acid with no treatmentFigure 1
Meta-analysis comparing tranexamic acid with no treatment. Mean blood loss up to two hours after delivery, 
expressed in millilitres.
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ommendation is based is low and recommends that fur-
ther clinical trials are conducted (personal
communication from Dr Metin Gülmezoglu, Department
of Reproductive Health and Research, World Health
Organization, February 2009).
Although the cost of tranexamic acid is likely to vary by
country and by producer, it is a simple and relatively inex-
pensive intervention. The time required to administer the
treatment is short and no additional training is required.
According to the British National Formulary, the cost of
two 500 mg ampoules of TXA (Cyklokapron® Pfizer) is
three pounds sterling. If there were clinical benefits from
using tranexamic acid, the benefits could easily justify the
costs, whether in high, middle or low-income countries.
Although the results from this systematic review and the
systematic review of the use of tranexamic acid in surgical
bleeding are encouraging, a high quality randomised con-
trolled trial comparing tranexamic acid to placebo is
needed to determine whether tranexamic acid improves
patient outcome in postpartum bleeding.
Conclusion
In conclusion, there is insufficient evidence from ran-
domised controlled trials to confirm or refute a clinically
important treatment effect from tranexamic acid in post
partum bleeding. The WOMAN trial is a large, interna-
tional, randomised, placebo controlled trial of tranexamic
acid in postpartum haemorrhage, and will provide this
evidence http://www.thewomantrial.Lshtm.ac.uk.
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